I
nhibition of nitric oxide (NO) synthesis produces hypertension in many species. 1, 2 Although this hypertension was initially attributed to the inhibition of endothelial NO synthesis, numerous studies suggest that inhibition of neuronal NO also plays an important role in blood pressure regulation. [3] [4] [5] [6] [7] A previous study demonstrated that increased sympathetic nerve activity plays a role in hypertension caused by chronic NO synthesis inhibition, and activation of the renin-angiotensin system in the nucleus tractus solitarii (NTS) of the brainstem via angiotensin II type 1 receptors is involved. 8 Chronic inhibition of NO synthesis might activate the Rho/ Rho-kinase pathway in the cardiac tissues or vasculature. 9, 10 The Rho/Rho-kinase pathway regulates the phosphorylation state of myosin light chains and contributes to smooth muscle contraction. 11 Y-27632, a specific Rho-kinase inhibitor, dramatically reduces blood pressure in rat models of hypertension. 12 In addition, Rho-kinase activity is augmented in hypertensive blood vessels 13 and inhibition of Rho-kinase induces preferential forearm vasodilatation in hypertensive patients, but not in normal subjects. 14 Thus, the Rho/Rhokinase pathway plays an important role in peripheral mechanisms of hypertension. [11] [12] [13] [14] RhoA and Rho-kinase are also distributed in the central nervous system. 15, 16 Activation of the Rho/Rho-kinase pathway in the NTS contributes to maintain basal blood pressure via the sympathetic nervous system, and this pathway might contribute to hypertensive mechanisms in spontaneously hypertensive rats. 17 It is unknown, however, whether activation of the Rho/Rho-kinase pathway also contributes to neurogenic hypertensive mechanisms caused by chronic NO synthesis inhibition. The aim of this study was to elucidate the role of the Rho/Rho-kinase pathway in the brainstem in neurogenic hypertension caused by chronic NO synthesis inhibition.
For this purpose, we microinjected Y-27632 into the NTS of Wistar-Kyoto (WKY) rats treated with the NO synthase inhibitor N -nitro-L-arginine methyl ester (L-NAME) and monitored systolic blood pressure (SBP), heart rate (HR), and renal sympathetic nerve activity (RSNA) under anesthesia. Furthermore, Y-27632 or vehicle was continuously infused intracisternally for 2 weeks with a mini-osmotic pump in WKY rats from the beginning of treatment with L-NAME, and SBP was measured. Finally, we compared RhoA and Rho-kinase activity in the NTS between control rats and L-NAME-treated rats.
Methods
This study was reviewed and approved by the Committee on Ethics of Animal Experiments, Kyushu University Graduate School of Medical Sciences and was conducted according to the guidelines for animal experiments of Kyushu University.
Microinjection Experiments With Rho-Kinase Inhibitors
Male WKY rats (280 to 340 g, 16 to 20 weeks old) obtained from an established colony at the Animal Research Institute of Kyushu University Faculty of Medicine 13 were used. The rats were randomly divided into two groups. The first group (control rats) received nontreated drinking water for 2 weeks. The second group received L-NAME (Sigma Chemical Co.) in the drinking water (1 mg/mL) for 2 weeks (L-NAME-treated rats). 8 The animals were anesthetized with sodium pentobarbital (50 mg/kg intraperitoneally), and a cannula (PE 50) was inserted into the right femoral artery for measurement of SBP and HR and into the femoral vein for infusion of pentobarbital (10 to 15 mg/kg per hour). 18 The anesthetized animals were artificially ventilated and placed in a stereotaxic frame. The dorsal surface of the medulla was exposed, the microinjection sites were defined according to an atlas of the rat brain, 19 and the depressor response was evoked by L-glutamate (40 pmol) microinjection. We then microinjected Y-27632 12 (0.4, 4, 40 pmol/siteϫ2 sites/side, bilaterally; injection volume: 80 nL/site). 17 In addition, we measured RSNA in another experiment. The left renal nerve was exposed with a left retroperitoneal flank incision. A pair of stainlesssteel bipolar electrodes was placed beneath the renal nerve to record multifiber RSNA, as described previously. 8 Background noise levels were determined by crushing the nerve at the end of the experiment. The background noise levels were subtracted during a later analysis of RSNA. Y-27632 was microinjected bilaterally into the NTS at only one site per side (40 pmol/site; injection volume: 80 nL/site) in this experiment because of the difficulty in stably recording RSNA without noise.
Repetitive Injection of Rho-Kinase Inhibitor
We performed repetitive injections of Y-27632 into the NTS of control rats (40 pmol/siteϫ2 sites/side, bilaterally; injection volume: 80 nL/site) to determine whether microinjection of Y-27632 elicited reproducible responses.
Microinjection of Hydralazine Into the NTS
We microinjected another vasodilator, hydralazine (50 pmol/site or 500 pmol/siteϫ1 site/side, bilaterally; injection volume: 50 nL/site), into the NTS of L-NAME-treated rats as a control for the vasodilator effect of Y-27632 20 to determine if the effects of microinjection of Y-27632 into the NTS were caused by an increase in local blood flow. Experimental procedures were the same as described.
Intravenous Infusion of Rho-Kinase Inhibitor
Intravenous Y-27632 (200 pmol or 1000 pmol/0.2 mL injection over a 50-second period with an infusion pump) was infused into L-NAME-treated rats to determine if microinjection or intracisternal infusion of Y-27632 acts on the vasculature.
Continuous Intracisternal Infusion Experiments With Rho-Kinase Inhibitor
The rats were randomly divided into four groups. The first group (L-NAME-VEH) received continuous infusion of vehicle (a-CSF, 0.25 L/h). The second group (L-NAME-Y-27632) received continuous infusion of Y-27632 (5 mmol/L, 0.25 L/h) intracisternally for 2 weeks with a mini-osmotic pump (Alzet model 1002; DURECT Corporation) from the beginning of treatment with L-NAME (1 mg/mL). The third group (control-VEH) received continuous infusion of vehicle (a-CSF, 0.25 L/h), and the fourth group (control-Y-27632) received continuous infusion of Y-27632 (5 mmol/L, 0.25 L/h) intracisternally for 2 weeks with a mini-osmotic pump while receiving nontreated drinking water. The rats were anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneally). The miniosmotic pump, filled with vehicle or Y-27632, was implanted subcutaneously in the back and connected to a polyethylene tube (PE 10). A small hole was then made in the atlantooccipital membrane that covers the dorsal surface of the medulla, and the tip of the tube was placed intracisternally and fixed in place with tissue adhesive. After full recovery from anesthesia, the rats were free to move about in their cages. The infusion was calculated to end after 14 days. SBP was measured using the tail-cuff method for 21 days.
Western Blot Analysis for Phosphorylation of the ERM Family
The rats were randomly divided into two groups. The first group (control rats) received nontreated drinking water for 2 weeks. The second group (L-NAME-treated rats) received L-NAME in drinking water (1 mg/mL) for 2 weeks. We then performed Western blot analysis to compare the RhoA or Rho-kinase activity in the NTS of control rats with that in L-NAME-treated rats. The animals were killed with an overdose of sodium pentobarbital, and the NTS tissue was obtained by punching out the NTS from coronal slices (2-mm thickness) of the brainstem with an 18-gauge needle (inside diameter: 950 m). The tissues were homogenized in a lysing buffer containing 40 mmol/L HEPES, 1% Triton X-100, 10% glycerol, and 1 mmol/L Na 3 VO 4 and 1 mmol/L PMSF. The tissue lysate was centrifuged and the supernatant collected. The protein concentration was determined using a BCA protein assay kit (Pierce Chemical). An aliquot of 15 g of protein from each sample was separated on 10% SDS-polyacrylamide gel. Proteins were subsequently transferred onto polyvinylidene difluoride membranes (Immobilon-P membrane; Millipore). Membranes were incubated with rabbit anti-phosphorylated ERM family members moesin (Thr558), ezrin (Thr567), and radixin (Thr564), which are the target proteins of Rho-kinase. 21 Membranes were then incubated with a horseradish peroxidaseconjugated horse anti-rabbit IgG antibody (1:10000). Immunoreactivity was detected by enhanced chemiluminescence autoradiography (ECL Western blotting detection kit; Amersham Pharmacia Biotechnology), and the film was analyzed with National Institutes of Health image software. Membrane and cytosolic proteins were isolated as described previously. 22 Western blot analysis was performed as mentioned using rabbit IgG polyclonal antibody to RhoA (1:1000; Santa Cruz Biotechnology) and horseradish peroxidaseconjugated goat anti-rabbit IgG antibody (1:10000).
Confirmation of Inhibitory Effects of Y-27632 on Rho-Kinase Activity
Ten days after the beginning of treatment with L-NAME and intracisternal infusion of Y-27632, the animals were killed with an overdose of sodium pentobarbital. The tissues of the brainstem were obtained and Western blot analysis for phosphorylation of the ERM family members was performed as described, except that 30 g of protein was applied to the gel.
Statistical Analysis
All values are expressed as meanϮSEM. ANOVA was used to compare SBP between rats co-treated with Y-27632 and vehicle. Any two mean values were compared by application of the Bonferroni procedure. An unpaired t test was used to compare the baseline values and the effects of each intervention between the groups. Differences were considered to be statistically significant when PϽ0.05.
Results

Effect of Microinjection of Y-27632 Into the NTS
Baseline SBP (175Ϯ11 versus 120Ϯ11 mm Hg; PϽ0.01; nϭ9 for each) was significantly higher in L-NAME-treated rats than in control rats, and HR (278Ϯ8 versus 281Ϯ3 bpm; nϭ9 for each) did not differ between the two groups. Baseline RSNA did not differ between the two groups (110Ϯ15 versus 86Ϯ12 spikes/sec; nϭ5 for each). Microinjection of Y-27632 into the NTS elicited a dose-dependent decrease in SBP and HR in both groups ( Figure 1A ). The magnitude of the decrease in SBP and HR was significantly greater in L-NAME-treated rats than in control rats ( Figure 1B) . Furthermore, in other experiments in which RSNA was recorded, microinjection of Y-27632 into the NTS elicited decreases in SBP, HR, and RSNA in both groups (Figure 2A ). The magnitude of the decreases in these variables was also significantly greater in L-NAME-treated rats than in control rats ( Figure 2B ). Moreover, the percent reduction of SBP (19Ϯ3 versus 10Ϯ3%; PϽ0.05; nϭ5 for each) or HR (15Ϯ2 versus 6Ϯ2%; PϽ0.01; nϭ5 for each) was significantly greater in L-NAME-treated rats than in control rats.
Effects of Repetitive Injection of Y-27632 Into the NTS
A similar depressor response was observed (40 pmol/siteϫ2 sites/side, bilaterally; injection volume: 80 nL/site) if there was a 20-minute interval between injections (⌬SBP: Ϫ32Ϯ3 versus Ϫ30Ϯ2 mm Hg; ⌬HR: Ϫ58Ϯ6 versus Ϫ56Ϯ7 bpm; nϭ3 for each), although the magnitude of the decrease in SBP was smaller at 10 minutes after the injection than that of the first injection (⌬SBP: Ϫ12Ϯ4 versus Ϫ29Ϯ3 mm Hg; ⌬HR: Ϫ20Ϯ3 versus Ϫ52Ϯ5 bpm; PϽ0.01; nϭ3 for each).
Effect of Microinjection of Hydralazine Into the NTS of L-NAME-Treated Rats
There was no significant change in SBP or HR after microinjection of hydralazine (50 pmol/siteϫ1 site/side; SBP: 179Ϯ5 versus 177Ϯ4 mm Hg; HR: 280Ϯ3 versus 284Ϯ2 bpm; nϭ3 for each; or 500 pmol/siteϫ1 site/side; SBP: 180Ϯ14 versus 177Ϯ11 mm Hg; HR: 288Ϯ9 versus 284Ϯ6 bpm; nϭ3 for each).
Intravenous Infusion of Rho-Kinase Inhibitor to L-NAME-Treated Rats
Intravenous infusion of Y-27632 (200 pmol or 1000 pmol/0.2 mL injection over 50-second period with infusion pump) elicited no significant changes in SBP or HR (200 pmol; SBP: 175Ϯ3 versus 176Ϯ5 mm Hg; HR: 278Ϯ5 versus 279Ϯ5 bpm; nϭ3 for each; or 1000 pmol; SBP: 177Ϯ12 versus 176Ϯ16 mm Hg; HR: 276Ϯ11 versus 274Ϯ6 bpm; nϭ3 for each). Figure 3A and 3B show the time course of SBP after treatment with L-NAME and intracisternal infusion of Y-27632. SBP was increased in the L-NAME-VEH and L-NAME-Y-27632 groups. Y-27632, however, significantly attenuated the increase in SBP. After discontinuing treatment with Y-27632, SBP increased to a level similar to that in L-NAME-VEH rats ( Figure 3A ). There was a small transient decrease in SBP from day 7 to day 11 compared with before treatment (day 0) in the control-Y-27632 group.
Blood Pressure Changes After the Beginning of L-NAME Treatment
Inhibitory Effects of Y27632 on Rho-Kinase Activity
To confirm the specific inhibitory effects of Y-27632 on Rho-kinase activity, we examined phosphorylation of the ERM family members, the target proteins of Rho-kinase, 21 in the brainstem of rats treated with Y-27632. The expression level of phosphorylation of the ERM family members was significantly reduced in the L-NAME--Y-27632 rats than in the L-NAME-VEH rats ( Figure 3C) . Furthermore, the extent of phosphorylation of the ERM family members significantly increased in L-NAME-treated rats compared with control rats ( Figure 3C ). In control rats, the expression level of phosphorylation of the ERM family members was slightly reduced in the control-Y-27632 rats compared with the control-VEH rats ( Figure 3D ).
RhoA and Rho-Kinase Activity in the NTS
The expression level of RhoA in membranes, which represents RhoA activity, 22 was greater in L-NAME-treated rats than in control rats ( Figure 4A) . Furthermore, the extent of . C, Western blot analysis for phosphorylated ERM family members, substrates of Rho-kinase, in the brainstem containing the NTS of L-NAME-treated rats. Data are expressed as the relative ratio to control rats, which was assigned a value of 1. Phosphorylation of the ERM family members was significantly increased in L-NAME-treated rats, and significantly reduced in the Y-27632-treated rats (nϭ4 for each). *PϽ0.05 vs L-NAME with vehicle. ##PϽ0.01 versus control rats. D, Western blot analysis for phosphorylated ERM family members in the brainstem containing the NTS of control rats. Data are expressed as relative ratio to control rats, which was assigned a value of 1. The expression level of phosphorylation of the ERM family members was slightly reduced in control-Y-27632 rats compared with control rats (nϭ3 for each). #PϽ0.05 vs control rats.
phosphorylation of the ERM family members, which represents Rho-kinase activity, 21 was greater in L-NAME-treated rats than in control rats ( Figure 4B ).
Discussion
The present study provides the first direct evidence that activation of the Rho/Rho-kinase pathway in the brainstem plays an important role in hypertension caused by chronic NO synthase inhibition. We demonstrated that: (1) microinjection of Rho-kinase inhibitor into the NTS significantly decreased SBP, HR, and RSNA in the L-NAME-treated rats than in control rats; (2) chronic intracisternal infusion of Rho-kinase inhibitor suppressed hypertension caused by chronic NO synthase inhibition; and (3) membrane translocation of RhoA and phosphorylation of the ERM family members were increased in the NTS of L-NAME-treated rats.
The results of the present study demonstrate that the membrane expression level of RhoA in the NTS was significantly greater in L-NAME-treated rats than in control rats, and microinjection of Y-27632 elicited a dose-dependent decrease of SBP and HR in L-NAME-treated rats and control rats. The magnitude of the decrease in SBP, HR, and RSNA was greater in L-NAME-treated rats than in control rats. In the microinjection study, we reproduced the responses to injections of Y-27632 into the bilateral NTS by repeating the injection after 20 minutes, although it was expected that enzymatic inhibition of Rho-kinase evoked by Y-27632 could be effective for a much longer period. 12,13 Thus, we cannot exclude the possibility that Y-27632, a pyridine derivative, might elicit an action like that of an agonist, or short-lived antagonist, at the specific receptors in the NTS. Furthermore, the extent of the phosphorylation of ERM family members in the NTS was greater in L-NAME-treated rats than in control rats. Previous studies demonstrated that the Rho/Rho-kinase pathway is activated in blood vessels of L-NAME-treated rats. 10 Thus, in the peripheral circulation, Rho-kinase is apparently involved in the mechanisms of L-NAME-induced hypertension. There is evidence that L-NAME crosses the blood-brain barrier when administered orally 23 and the sympathetic nervous system is involved primarily in the maintenance, rather than initiation, of L-NAME-induced hypertension. 24, 25 Furthermore, activation of the Rho/Rho-kinase pathway in the NTS plays an important role in the maintenance of the basal arterial blood pressure via the sympathetic nervous system. 17 In addition, activation of the pathway might be involved in the central nervous system mechanisms of hypertension in spontaneously hypertensive rats. 17 Our results indicate that the Rho/Rho-kinase pathway is activated in the NTS of L-NAME-treated rats and contributes, at least in part, to the central nervous system mechanisms of hypertension caused by chronic NO synthase inhibition.
The Rho/Rho-kinase pathway plays an important role in vascular tone regulation. Because the NTS is rich in blood vessels, it is possible that inhibition of Rho-kinase activity in the NTS changes blood pressure by increasing local blood flow. Therefore, we microinjected another vasodilator, hydralazine, bilaterally into the NTS of L-NAME-treated rats and confirmed that hydralazine did not alter blood pressure. Thus, the effects of the Rho-kinase inhibitor in the NTS on blood pressure regulation were not caused by its local vasodilator effect. 20 Our findings suggest that endogenous Rho-kinase in the brainstem plays an important role in L-NAME-induced hypertension. As demonstrated by the chronic experiments, the L-NAME-induced increase in blood pressure was significantly suppressed during intracisternal Y-27632 infusion. Nonspecific effects caused by the surgical procedure are unlikely because continuous intracisternal infusion of vehicle using the same devices did not suppress the SBP elevation, and after discontinuing the Y-27632 infusion, SBP increased to a level similar to that in L-NAME-VEH rats. In addition, phosphorylation of ERM family members in the brainstem was significantly increased in L-NAME-VEH rats and reduced in the L-NAME-Y-27632 rats, which strongly suggests that the Rho/Rho-kinase pathway in the brainstem of L-NAMEtreated rats activates Rho-kinase activity in vivo and Y27632 suppresses it.
In the present study, intracisternal infusion of Y-27632 prevented the increase in SBP on the first day of L-NAME treatment, which is not consistent with the reports that the Figure 4 . Expression of membranous RhoA protein and phosphorylated ERM family members in the NTS. Data are expressed as relative ratio to control rats, which was assigned a value of 1. A, Western blot analysis demonstrating RhoA expression in membrane and cytosol in the NTS. The expression level of membranous RhoA protein was significantly higher in L-NAME-treated rats than control rats (nϭ3; **PϽ0.01 vs control rats). B, Western blot analysis demonstrating the expression of phosphorylated ERM family members in the NTS. The expression level of phosphorylated ERM family members was significantly higher in L-NAME-treated rats than in control rats (nϭ3; **PϽ0.01 vs control rats).
initial increase in SBP with L-NAME is caused by the inhibition of vascular NO. [3] [4] [5] [6] [7] The latency of the onset of the sympathectomy-sensitive component of intravenous infusion of L-NAME-induced hypertension, however, was 1 to 2 hours. 24 The latency of onset of neural component after oral administration of L-NAME might be longer than intravenous infusion; 24 hours is when the neural component of L-NAME-induced blood pressure elevation becomes apparent. Furthermore, the effect of intracisternal infusion of Y-27632 on SBP was expected to begin much faster than that of oral administration of L-NAME. Therefore, intracisternal infusion of Y-27632 might prevent L-NAME-induced blood pressure elevation.
To exclude the possibility of vascular action of intracisternal infusion of Y-27632, we intravenously infused Y-27632 (1000 pmol/0.2 mL injection over 50-second period with an infusion pump) into L-NAME-treated rats. This amount of Y-27632 was the same as that of an 8-hour intracisternal infusion dose with the pump used in the present study and elicited no significant change in SBP or HR. Furthermore, Y-27632 was intracisternally infused into the control rats. In the control rats, Y-27632 induced a small transient decrease in SBP from day 7 to day 11 compared with before treatment (day 0). In addition, the expression level of phosphorylation of the ERM family members in the brainstem was slightly reduced in control-Y-27632 rats compared with control-VEH rats. SBP and the extent of phosphorylation of the ERM family members was significantly decreased in control-Y27632 rats, although the magnitudes were small because of indirect effects of Y-27632 in the NTS and other brain areas. These results suggest that the Rho/Rho-kinase pathway in the brainstem of normotensive rats contributes somewhat to blood pressure regulation. 17 This result is also consistent with the results of our previous study, demonstrating transfection of adenovirus encoding dominant-negative Rho-kinase into the NTS in normotensive WKY rats. 17 There is a possibility that the greater effect in L-NAMEtreated rats was caused by differences in Rho-kinase activity somewhere downstream from the NTS. The rostral ventrolateral medulla (RVLM) neurons are activated in rats with chronic NO synthase inhibition. 26 Intracisternal infusion of a drug might affect neurons not only in the NTS but also in the rostral ventrolateral medulla. 27 Therefore, intracisternal infusion of Y-27632 might also alter neuronal activity in areas other than the NTS, such as the rostral ventrolateral medulla in L-NAME-treated rats. We demonstrated, however, that a greater depressor effect of Y-27632 on blood pressure and/or RSNA in L-NAME-treated rats than in control rats in microinjection experiments. In addition, RhoA and Rhokinase activity was enhanced in L-NAME-treated rats compared with control rats. Thus, we believe that the effect of Y-27632 is at least partly mediated by inhibition of Rhokinase activity in the NTS. Further studies are needed to determine whether other cardiovascular centers of the brainstem are affected by chronic NO synthesis inhibition or intracisternal infusion of Y-27632.
In conclusion, we demonstrated that the Rho/Rho-kinase pathway in the NTS is activated in L-NAME-treated rats as compared with control rats. Activation of the Rho/Rho-kinase pathway plays an important role in L-NAME-induced hypertension.
Perspectives
We do not know the mechanisms by which activation of the Rho/Rho-kinase pathway in the NTS alters arterial blood pressure via the sympathetic nervous system or the cause of the greater activation the Rho/Rho-kinase pathway in L-NAMEtreated rats. A recent study demonstrated that activity of the renin-angiotensin system in the NTS is increased by chronic NO synthase inhibition. 8 Accumulating evidence suggests that Rhokinase is substantially involved in the signal transduction initiated by many vasoactive substances, such as angiotensin II. 28, 29 Indeed, a considerable amount of evidence suggests that angiotensin II in the central nervous system contributes to the neural mechanisms of hypertension. 27 Therefore, activation of the Rho/Rho-kinase pathway in the NTS of L-NAME-treated rats might be elicited by activation of the renin-angiotensin system in the NTS. Furthermore, the neuronal Rho/Rho-kinase pathway contributes to dendritic spine formation. 30, 31 Dendritic spines form postsynaptic sites in excitatory synapses in the central nervous system. Recent studies suggest that morphological changes in dendritic spines occur rapidly 32 and are associated with glutamate sensitivity. 33 Indeed, there are structural differences of dendritic spines in the NTS between WKY rats and SHR. 34 Therefore, the Rho/Rho-kinase pathway affects synaptic transmission in the NTS and might also be involved in baroreflex function. Further studies are needed to clarify the mechanisms responsible for our observations.
